Skip to content

Immune Modulation Therapy for Pompe Disease

Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02525172
Enrollment
8
Registered
2015-08-17
Start date
2015-08-31
Completion date
2020-07-31
Last updated
2016-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pompe Disease

Keywords

immune modulation therapy, acid α-glucosidase, antibody

Brief summary

The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.

Interventions

DRUGRituximab
DRUGBortezomib
DRUGMethotrexate

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* The patient (and/or patient's legal guardian if patient is \< 18years) must provide written informed consent prior to any study-related procedures that are performed; * The patient must have a confirmed diagnosis of Pompe disease defined as a documented acid α-glucosidase (GAA) enzyme deficiency from blood samples or 2 GAA gene mutations; * The patient (and/or legal guardian) must have ability to comply with clinical protocol; * Regimen A only: The patient is receiving enzyme replacement therapy, exhibits clinical decline, and has persistent high anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers and/or tested positive for antibodies that inhibit enzymatic activity and/or uptake of Myozyme; * Regimen B only: The patient is cross-reactive immune material (CRIM) -negative AND have not received Myozyme infusion prior to enrollment

Exclusion criteria

* The patient is at risk of reactivation or is a carrier of Hepatitis B or Hepatitis C; * The patient is at risk of reactivation of tuberculosis or has regular contact with individuals who are being actively treated for tuberculosis; * The patient has used any investigational product (other than alglucosidase alfa) within 30 days prior to study enrollment; * The patient is pregnant or lactating; * The patient has had or is required to have any live vaccination within one month prior to enrollment.

Design outcomes

Primary

MeasureTime frame
anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers decrease6 months

Countries

Taiwan

Contacts

Primary ContactYin-Hsiu Chien
chienyh@ntu.edu.tw+886223123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026